Positive judgement on the international patent application for Temodex
Double Bond Pharmaceutical AB has now received a positive judgement on a comprehensive review of the international patent application for Temodex – the novel therapy against brain cancer. The European Patent Office (EPO) was selected as the Examining Authority to get a critical and detailed analysis on how the application will be reviewed and evaluated by EPO in the European phase. The international patent application (PCT) for Temodex was submitted by Double Bond Pharmaceutical on April 28th 2017. "It is extremely important for Double Bond Pharmaceutical that EPO considers our patent